Advances in Nucleic Acid Therapeutics Detection and Biological Imaging (Broadcast 2)
Earn a Certificate of Live Attendance
AI Webinar Explorer available after event
About this webinar
As nucleic acid therapeutics advance, researchers increasingly need tools that provide more than confirmation of target engagement or tissue exposure. Understanding the localization and distribution of modified oligonucleotides across cells, tissues and biological compartments, as well as how these patterns relate to biological activity can provide critical insights into therapeutic development. Advanced imaging approaches allow researchers to visualize these molecules in their biological context and investigate questions beyond traditional quantitative measurements.
This webinar will explore how antibody-based detection methods and advanced microscopy technologies can be combined to visualize and characterize nucleic acid therapeutics in biological samples. Attendees will learn how these complementary approaches provide insights into cellular uptake, tissue distribution and localization patterns, deepening the understanding of therapeutic behavior.
The first presentation will highlight how advanced imaging technologies address challenges in oncology research, from investigating disease biology to generating quantitative insights from biological samples. Through application-focused examples, attendees will explore how complementary imaging and analysis approaches support image acquisition, data interpretation and biological discovery. The session will also discuss how specialized microscopy capabilities and scientific expertise support complex biological research.
The second presentation will examine how modification-specific antibodies detect chemically modified oligonucleotides across therapeutic modalities. Through published research and examples involving diffuse midline glioma, attendees will explore how these antibodies can be used in imaging workflows to visualize nucleic acid therapeutics in cell-based and in vivo models. The discussion will highlight applications in cellular uptake and biodistribution studies, along with considerations for interpreting detection patterns and imaging results.
Register for this webinar to learn how antibody-based detection and advanced imaging techniques can improve the visualization and characterization of nucleic acid therapeutics in biological samples.
Who should attend
- Nucleic Acid and Oligonucleotide Therapeutic Researchers
- Cancer Biologists and Oncology Researchers
- Cell and Molecular Biologists
- Drug Delivery and Preclinical Research Scientists
- Microscopy, Imaging and Image Analysis Specialists
- Translational Researchers
What you will learn
- How advanced imaging technologies and image analysis can support biological research and the interpretation of complex samples
- The use of universal detection reagents to visualize chemically modified oligonucleotides in cells and tissues
- Approaches for investigating cellular uptake, tissue distribution and the localization of nucleic acid therapeutics in biological models
- How specialized microscopy capabilities and scientific expertise can support advanced imaging research
Featured Speakers
Seth Farrier
Seth Farrier is a Senior Research Scientist in the Research & Development department at Rockland Immunochemicals, with over 10 years of experience in immunoassay development and analytical characterization. His work focuses on supporting RNA therapeutic development through antibody-based tools, including the ModDetect platform for sequence-independent detection of modified oligonucleotides. He develops and applies immunoassay approaches, including ELISA and BLI, to enable quantification, localization and trafficking studies of oligonucleotide therapeutics across biological matrices. His work spans method development, optimization and assay qualification, supporting bioanalytical and biodistribution workflows for RNA-based modalities.
Peter Favreau
Peter Favreau is Business Development Manager for North America Biotech & Pharma at ZEISS Life Sciences Solutions, where he works with biotechnology and pharmaceutical organizations to advance imaging-enabled workflows across oncology, advanced therapeutics and drug development. He collaborates with researchers to apply cutting-edge microscopy and analysis solutions to complex biological questions, helping accelerate scientific discovery from early research through translational applications.
Partner for this event
Rockland Immunochemicals
Established in 1962, Rockland Immunochemicals, Inc. is a privately held biotechnology company specializing in antibody and protein production near Philadelphia, Pennsylvania. As a trusted partner to the global life science community, Rockland supports academic, diagnostic, and biopharma research with high-quality, validated antibody-based tools. Our products are designed to advance discovery and ensure confidence in complex applications.